FTC Forms Health Care Task Force for Enhanced Regulation

The Federal Trade Commission (FTC) has announced the formation of a Health Care Task Force to enhance enforcement and advocacy within the health care sector. This initiative signals a potential increase in regulatory scrutiny, focusing on transparency among pharmacy benefit managers, anticompetitive mergers, patent practices, and misleading health care marketing.

The new Health Care Task Force will play a pivotal role in the broader regulatory environment, potentially collaborating with the U.S. Department of Justice (DOJ) and the U.S. Department of Health and Human Services (HHS). Both agencies have heightened their oversight activities in the health care industry, reflecting ongoing regulatory attention to industry practices.

FTC Chairman Andrew Ferguson announced the task force in a memo dated March 20, 2026. The task force comprises members from various FTC departments, including Competition, Consumer Protection, and Economics. Ferguson emphasized that the task force's creation aligns with the FTC’s mission to protect consumers from unfair practices and promote fair competition.

Initial priorities for the task force were not specified, but it appears aligned with President Trump’s administration priorities, such as enhancing pricing transparency, reducing costs, and increasing industry accountability. Instead of proposing new regulations, the task force will focus on enforcement actions related to deceptive or unfair practices.

As the task force begins operations, health care organizations should prepare for increased regulatory oversight. This development follows substantial recoveries under the False Claims Act by the DOJ, particularly in managed care and prescription drug sectors. Organizations are advised to review their compliance strategies and consult legal advisors regarding these regulatory changes.